Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of “Moderate Buy” by Brokerages

Guardant Health, Inc. (NASDAQ:GH) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $37.70.

A number of equities research analysts have recently commented on GH shares. Guggenheim reiterated a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. JPMorgan Chase & Co. decreased their price target on Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Piper Sandler cut their price objective on Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. The Goldman Sachs Group reduced their price objective on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, April 15th. Finally, Craig Hallum began coverage on shares of Guardant Health in a research report on Wednesday, April 24th. They issued a “buy” rating and a $28.00 target price on the stock.

Guardant Health Stock Performance

Shares of GH opened at $18.88 on Friday. Guardant Health has a 52-week low of $15.81 and a 52-week high of $41.06. The firm has a market capitalization of $2.30 billion, a PE ratio of -4.41 and a beta of 0.92. The firm has a 50-day moving average price of $18.39 and a 200 day moving average price of $22.53. The company has a quick ratio of 6.24, a current ratio of 6.54 and a debt-to-equity ratio of 7.18.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The firm had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. On average, sell-side analysts anticipate that Guardant Health will post -3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Guardant Health news, insider Kumud Kalia acquired 2,187 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was acquired at an average price of $17.82 per share, with a total value of $38,972.34. Following the transaction, the insider now owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. CWM LLC grew its holdings in shares of Guardant Health by 137.1% during the 3rd quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after purchasing an additional 569 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Guardant Health during the third quarter worth $818,000. Cambridge Investment Research Advisors Inc. increased its holdings in Guardant Health by 81.1% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 25,684 shares of the company’s stock valued at $761,000 after buying an additional 11,498 shares during the period. Raymond James & Associates raised its stake in shares of Guardant Health by 7.9% in the 3rd quarter. Raymond James & Associates now owns 134,162 shares of the company’s stock valued at $3,977,000 after buying an additional 9,770 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Guardant Health by 7.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,541 shares of the company’s stock worth $698,000 after acquiring an additional 1,531 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.